Comments
Cadila Healthcare said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest pain. The drug firm has also received final approval from the US Food and Drug Administration for desonide cream, used to treat a variety of skin conditions such as eczema, dermatitis, allergies and rash, the company said in a filing to the BSE.
It will be manufactured at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, it said.
Shares of Cadila Healthcare closed 2 per cent higher at ₹254.20 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.